Contact
searchSearch
HMP Global
Login

Multiple Myeloma News (ASH) Basic Listing

Updates in Multiple Myeloma
From the ASH Annual Meeting & Exposition

Robert Orlowski, MD, PhD
Conference Coverage
Linvoseltamab Demonstrates Deep, Durable Responses as Frontline Myeloma Therapy: LINKER-MM4 Trial
12/17/2025
Robert Orlowski, MD, PhD
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
Emma Searle, MD
Videos
Teclistamab Combined With Subcutaneous Daratumumab and Lenalidomide in Patients With Multiple Myeloma
02/05/2023
Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.
Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.
Emma Searle, MD, discusses...
02/05/2023
Oncology
Ajari Chari, MD
Videos
Talquetamab Demonstrates Robust Efficacy, Manageable Safety in Patients With Heavily Pretreated R/R Multiple Myeloma
12/12/2022
At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.
At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.
At the 2022 ASH Annual Meeting...
12/12/2022
Oncology

Recent News

Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
News
Low-Dose CT Screening Reduces Lung Cancer Mortality in a Non–Risk-Based Population
03/26/2026
Emily Estrada
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective...
03/26/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
News
Ceralasertib Plus Durvalumab Does Not Improve Outcomes in Advanced Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3...
03/26/2026
Oncology
News
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3...
03/26/2026
Oncology
News
Osimertinib Plus Local Consolidative Therapy Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2...
03/26/2026
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use